Instead, we performed functional experiments in lung fibroblasts and analyzed the responses of fibroblasts derived from patients with lung fibrosis to pirfenidone for determining the utility of CTHRC1 as a potential therapeutic target and predicting pirfenidone responses in lung fibrosis. This evidence concerns the gene CTHRC1 and pulmonary fibrosis.